“The North American neuromodulation market is expected to reach $4,854.4 million by 2019 at a CAGR of 10.5% from 2014 to 2019.
Neuromodulation is defined as the use of technology to regulate the nervous system involving various processes, such as therapeutic alteration, stimulation, modification, inhibition, and others for the proper functioning of the body. This is carried out with the help of implantable devices. These devices are usually neural stimulators, which are used to treat various chronic and acute pain syndromes, dystonia, movement disorders, and spasticity. There are various types of stimulators that are usually used to stimulate the spinal cord and brain. The types include spinal cord stimulator, deep brain stimulator, gastric electrical stimulator, vagus nerve stimulator, and sacral nerve stimulator.
The North America neuromodulation market has been segmented by procedure, modality, and geography. On the basis of procedure, the market is further segmented into internal and external stimulation. The internal stimulation segment accounted for a higher market share of 87.4% in the neuromodulation market. The market based on modality covers internal and external modality. The internal modality segment accounted for a higher market share of 85.9%in the neuromodulation market. Further, the market is segmented in terms of geography. Countries, such as the U.S., Canada, and Mexico are included in this market report. The market in the U.S. accounted for the highest share.
The report has profiled the leading players of this market along with the strategies (New product launches, approvals, and acquisitions) adopted by them to sustain and strengthen their position in the North America neuromodulation market. Medtronic Plc. (U.S.), St. Jude Medical (U.S.), Boston Scientific Corp. (U.S.), Cyberonics Inc. (U.S.), Biocontrol Medical (U.S.), and Greatbatch (U.S.) are some of the key players operating in this market.
Reasons to Buy the Report:
From an insight perspective, this research report has focused on various levels of analysis—industry analysis ,market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss the basic views on the competitive landscape, usage patterns, emerging- and high-growth segments of the North America neuromodulation market, high-growth regions and countries and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market, share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share.
The report provides insights on the following pointers:
• Product Analysis and Development: Detailed insights on upcoming technologies, research and development activities, and new product launches in the North America neuromodulation market. Usage pattern/penetration rate (in-depth trend analysis) of products (segment-wise) and purchasing data.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for North America neuromodulation market across geographies, exploit new distribution channels, new clientele base and different pricing policies.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments decisions in the North America neuromodulation market. Detailed description regarding the related and unrelated diversification pertaining to this market.
• Competitive Assessment: In-depth assessment of market shares, company share analysis of the key players forecasted till 2019. Develop business strategies and manufacturing capabilities of leading players enhance the bottom line of the companies in the North America neuromodulation market.
• Product/Brand Perception Analysis: Comprehensive study of customers perception and behavior through our inbuilt social connect tool (digital marketing language) checking the virality and tonality of blogs.
”
“TABLE OF CONTENTS
1 INTRODUCTION 9
1.1 OBJECTIVES OF THE STUDY 9
1.2 MARKET SEGMENTATION & COVERAGE 9
1.3 STAKEHOLDERS 10
2 RESEARCH METHODOLOGY 11
2.1 INTEGRATED ECOSYSTEM OF THE INTERNAL NEUROMODULATION MARKET 11
2.2 ARRIVING AT THE INTERNAL NEUROMODULATION MARKET SIZE 12
2.2.1 TOP-DOWN APPROACH 12
2.2.2 BOTTOM-UP APPROACH 14
2.2.3 MACROINDICATOR-BASED APPROACH 15
2.3 ASSUMPTIONS 16
3 EXECUTIVE SUMMARY 17
4 MARKET OVERVIEW 19
4.1 INTRODUCTION 19
4.2 INTERNAL NEUROMODULATION MARKET: COMPARISON WITH NEUROMODULATION (PARENT) MARKET 19
4.3 MARKET DRIVERS AND INHIBITORS 21
5 NORTH AMERICA INTERNAL NEUROMODULATION MARKET, BY TYPE 23
5.1 INTRODUCTION 24
5.2 NORTH AMERICA SPINAL CORD STIMULATION MARKET, BY COUNTRY 25
5.3 NORTH AMERICA DEEP BRAIN STIMULATION MARKET, BY COUNTRY 26
5.4 NORTH AMERICA SACRAL NERVE STIMULATION MARKET, BY COUNTRY 27
5.5 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY COUNTRY 28
5.6 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY 29
6 NORTH AMERICA INTERNAL NEUROMODULATION MARKET, BY APPLICATION 30
6.1 INTRODUCTION 31
6.2 NORTH AMERICA INTERNAL NEUROMODULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY 32
6.3 NORTH AMERICA INTERNAL NEUROMODULATION MARKET FOR TREMOR,
BY COUNTRY 33
6.4 NORTH AMERICA INTERNAL NEUROMODULATION MARKET FOR DEPRESSION,
BY COUNTRY 34
6.5 NORTH AMERICA INTERNAL NEUROMODULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY 35
7 NORTH AMERICA INTERNAL NEUROMODULATION MARKET, BY GEOGRAPHY 37
7.1 INTRODUCTION 38
7.2 U.S. INTERNAL NEUROMODULATION MARKET 39
7.2.1 U.S. INTERNAL NEUROMODULATION MARKET, BY APPLICATION 40
7.2.2 U.S. INTERNAL NEUROMODULATION MARKET, BY TYPE 42
7.3 CANADA INTERNAL NEUROMODULATION MARKET 43
7.3.1 CANADA INTERNAL NEUROMODULATION MARKET, BY APPLICATION 44
7.3.2 CANADA: INTERNAL NEUROMODULATION MARKET, BY TYPE 46
7.4 MEXICO INTERNAL NEUROMODULATION MARKET 47
7.4.1 MEXICO INTERNAL NEUROMODULATION MARKET, BY APPLICATION 48
7.4.2 MEXICO INTERNAL NEUROMODULATION MARKET, BY TYPE 50
8 COMPETITIVE LANDSCAPE 52
8.1 INTERNAL NEUROMODULATION MARKET, BY COMPANY 52
8.2 COMPANY PRESENCE IN INTERNAL NEUROMODULATION MARKET, BY TYPE 53
8.3 NEW PRODUCT LAUNCHES 54
8.4 REGULATORY APPROVALS 54
9 COMPANY PROFILES 55
(Overview, Financials, Products & Services, Strategy, and Developments)*
9.1 BOSTON SCIENTIFIC CORPORATION 55
9.2 CERBOMED GMBH 58
9.3 CYBERONICS, INC. 59
9.4 DEPUY SYNTHES COMPANIES 61
9.5 ENTEROMEDICS, INC. (U.S.) 64
9.6 MEDTRONIC, INC. (U.S.) 66
9.7 ST. JUDE MEDICAL 69
9.8 SYNAPSE BIOMEDICAL, INC. 72
9.9 UROPLASTY, INC. (U.S.) 73
*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted company
10 APPENDIX 75
10.1 CUSTOMIZATION OPTIONS 75
10.1.1 PRODUCT ANALYSIS 75
10.1.2 EPIDEMIOLOGY DATA 75
10.1.3 SURGEONS/PHYSICIANS PERCEPTION ANALYSIS 75
10.1.4 REGULATORY FRAMEWORK 75
10.2 RELATED REPORTS 76
10.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 77
10.3.1 SNAPSHOTS 78
“
“LIST OF TABLES
TABLE 1 GLOBAL INTERNAL NEUROMODULATION PEER MARKET SIZE, 2014 (USD MN) 13
TABLE 2 NORTH AMERICAN INTERNAL NEUROMODULATION MARKET: MACROINDICATORS,
BY COUNTRY, 2013 (USD MN) 15
TABLE 3 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET: COMPARISON WITH NEUROMODULATION (PARENT) MARKET, 2013 – 2019 (USD MN) 20
TABLE 4 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE,
2013 – 2019 (USD MN) 20
TABLE 5 NORTH AMERICA INTERNAL NEUROMODULATION MARKET: DRIVERS AND INHIBITORS 21
TABLE 6 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE,
2013 – 2019 (USD MN) 24
TABLE 7 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY,
2013–2019 (USD MN) 25
TABLE 8 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY,
2013–2019 (USD MN) 26
TABLE 9 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY COUNTRY,
2013 – 2019 (USD MN) 27
TABLE 10 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY,
2013 – 2019 (USD MN) 28
TABLE 11 NORTH AMERICA: GASTRIC ELECTRICAL MARKET, BY COUNTRY,
2013 – 2019 (USD MN) 29
TABLE 12 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY APPLICATION,
2013 – 2019 (USD MN) 32
TABLE 13 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2013 – 2019 (USD MN) 33
TABLE 14 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET FOR TREMOR,
BY COUNTRY, 2013 – 2019 (USD MN) 34
TABLE 15 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET FOR DEPRESSION,
BY COUNTRY, 2013 – 2019 (USD MN) 35
TABLE 16 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2013 – 2019 (USD MN) 36
TABLE 17 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY,
2013 – 2019 (USD MN) 38
TABLE 18 U.S.: INTERNAL NEUROMODULATION MARKET, BY APPLICATION,
2013-2019 (USD MN) 40
TABLE 19 U.S.: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2013 – 2019 (USD MN) 42
TABLE 20 CANADA: INTERNAL NEUROMODULATION MARKET, BY APPLICATION,
2013-2019 (USD MN) 44
TABLE 21 CANADA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2013 – 2019 (USD MN) 46
TABLE 22 MEXICO: INTERNAL NEUROMODULATION MARKET, BY APPLICATION,
2013-2019 (USD MN) 48
TABLE 23 MEXICO: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2013 – 2019 (USD MN) 50
TABLE 24 INTERNAL NEUROMODULATION MARKET: BY COMPANY 52
TABLE 25 INTERNAL NEUROMODULATION MARKET: COMPANY SHARE ANALYSIS, 2013(%) 52
TABLE 26 NORTH AMERICA INTERNAL NEUROMODULATION MARKET: NEW PRODUCT LAUNCHES 54
TABLE 27 NORTH AMERICA INTERNAL NEUROMODULATION MARKET: REGULATORY APPROVALS 54
TABLE 28 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS, BY SEGMENT,
2009 – 2013 (USD MN) 56
TABLE 29 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS, BY REGION,
2009 – 2012 (USD MN) 56
TABLE 30 CYBERONICS, INC.: KEY FINANCIALS, 2009 – 2013 (USD MN) 59
TABLE 31 JOHNSON & JOHNSON, INC. : KEY FINANCIALS, BY SEGMENT, 2009 – 2013 (USD MN) 62
TABLE 32 JOHNSON & JOHNSON, INC.: KEY FINANCIALS, 2009 – 2013 (USD MN) 62
TABLE 33 MEDTRONIC, INC.: KEY FINANCIALS, BY SEGMENT, 2009 – 2013 (USD MN) 67
TABLE 34 MEDTRONIC, INC.: KEY FINANCIALS, 2009 – 2013 (USD MN) 67
TABLE 35 ST. JUDE MEDICAL: KEY FINANCIALS, BY SEGMENT, 2011 – 2013 (USD MN) 69
TABLE 36 ST. JUDE MEDICAL: KEY FINANCIALS, BY GEOGRAPHY, 2009 – 2013 (USD MN) 70
TABLE 37 UROPLASTY, INC.: KEY FINANCIALS, BY COUNTRY, 2010 – 2013 (USD MN) 73
“
“LIST OF FIGURES
FIGURE 1 NORTH AMERICAN INTERNAL NEUROMODULATION MARKET: SEGMENTATION & COVERAGE 10
FIGURE 2 INTERNAL NEUROMODULATION MARKET: INTEGRATED ECOSYSTEM 11
FIGURE 3 RESEARCH METHODOLOGY 12
FIGURE 4 TOP-DOWN APPROACH 13
FIGURE 5 BOTTOM-UP APPROACH 14
FIGURE 6 MACROINDICATOR-BASED APPROACH 15
FIGURE 7 NORTH AMERICAN INTERNAL NEUROMODULATION MARKET SNAPSHOT 18
FIGURE 8 INTERNAL NEUROMODULATION MARKET: COMPARISON WITH NEUROMODULATION (PARENT) MARKET 19
FIGURE 9 NORTH AMERICA INTERNAL NEUROMODULATION MARKET, BY TYPE, 2013 (USD MN) 20
FIGURE 10 NORTH AMERICA INTERNAL NEUROMODULATION MARKET, BY TYPE,
2014 VS. 2019 (USD MN) 24
FIGURE 11 NORTH AMERICA SPINAL CORD STIMULATION MARKET, BY COUNTRY,
2013–2019 (USD MN) 25
FIGURE 12 NORTH AMERICA DEEP BRAIN STIMULATION MARKET, BY COUNTRY,
2013–2019 (USD MN) 26
FIGURE 13 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY COUNTRY,
2013 – 2019 (USD MN) 27
FIGURE 14 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY COUNTRY,
2013 – 2019 (USD MN) 28
FIGURE 15 NORTH AMERICA GASTRIC ELECTRICAL MARKET, BY COUNTRY, 2013 – 2019 (USD MN) 29
FIGURE 16 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY APPLICATION,
2013 – 2019 (USD MN) 31
FIGURE 17 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2013 – 2019 (USD MN) 32
FIGURE 18 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET FOR TREMOR,
BY COUNTRY, 2013 – 2019 (USD MN) 33
FIGURE 19 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET FOR DEPRESSION,
BY COUNTRY, 2013 – 2019 (USD MN) 34
FIGURE 20 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2013 – 2019 (USD MN) 35
FIGURE 21 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET: GROWTH ANALYSIS,
BY GEOGRAPHY, 2013-2019 (USD MN) 38
FIGURE 22 U.S. INTERNAL NEUROMODULATION MARKET OVERVIEW, 2014 & 2019 (%) 39
FIGURE 23 U.S. INTERNAL NEUROMODULATION MARKET, BY APPLICATION, 2013-2019 (USD MN) 40
FIGURE 24 U.S. INTERNAL NEUROMODULATION MARKET: APPLICATION SNAPSHOT,
2014 VS. 2019 41
FIGURE 25 U.S. INTERNAL NEUROMODULATION MARKET, BY TYPE, 2013 – 2019 (USD MN) 42
FIGURE 26 U.S. INTERNAL NEUROMODULATION MARKET SHARE, BY TYPE, 2014 VS. 2019 (%) 43
FIGURE 27 CANADA INTERNAL NEUROMODULATION MARKET OVERVIEW, 2014 & 2019 (%) 43
FIGURE 28 CANADA INTERNAL NEUROMODULATION MARKET, BY APPLICATION,
2013-2019 (USD MN) 44
FIGURE 29 CANADA INTERNAL NEUROMODULATION MARKET: APPLICATION SNAPSHOT,
2014 VS. 2019 45
FIGURE 30 CANADA INTERNAL NEUROMODULATION MARKET, BY TYPE, 2013 – 2019 (USD MN) 46
FIGURE 31 CANADA INTERNAL NEUROMODULATION MARKET SHARE, BY TYPE, 2014 VS.2019 (%) 47
FIGURE 32 MEXICO INTERNAL NEUROMODULATION MARKET OVERVIEW, 2014 & 2019 (%) 47
FIGURE 33 MEXICO INTERNAL NEUROMODULATION MARKET, BY APPLICATION,
2013 – 2019 (USD MN) 48
FIGURE 34 MEXICO INTERNAL NEUROMODULATION MARKET: APPLICATION SNAPSHOT,
2014 VS. 2019 49
FIGURE 35 MEXICO INTERNAL NEUROMODULATION MARKET, BY TYPE, 2013- 2019 (USD MN) 50
FIGURE 36 MEXICO INTERNAL NEUROMODULATION MARKET SHARE, BY TYPE, 2014 VS. 2019 (%) 51
FIGURE 37 INTERNAL NEUROMODULATION: COMPANY PRODUCT COVERAGE, BY TYPE, 2013 53
FIGURE 38 BOSTON SCIENTIFIC CORPORATION: BUSINESS REVENUE MIX, 2013 55
FIGURE 39 JOHNSON & JOHNSON, INC.: REVENUE MIX, 2013 61
FIGURE 40 MEDTRONIC, INC.: REVENUE MIX, 2013 66
FIGURE 41 ST. JUDE MEDICAL: REVENUE MIX, 2013 69
“
